Vikas Lifecare has already paid Rs. 25 million to the Advik bankers till date and the remaining amount shall also be paid within July 2021, making Advik a debt free company
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
The facility is expected to be completed in 2024
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde, executive vice president, Thermo Fisher.
Subscribe To Our Newsletter & Stay Updated
